Adamis Pharmaceuticals Corp (ADMP) [Rocket]

Overview

Adamis Pharmaceuticals Corp (ADMP)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/12/2023	DEFC14A	Form DEFC14A - Definitive proxy statement, contested solicitations:
10/10/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
10/02/2023	PREC14A	Form PREC14A - Preliminary proxy statements, contested solicitations:
08/21/2023	8-K	Quarterly results
08/14/2023	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/10/2023	SC 13G	INTRACOASTAL CAPITAL, LLC reports a 7.6% stake in Adamis Pharmaceuticals Corporation
08/03/2023	8-K	Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	4.8	2.2	2.8	22.1	15.1	13.1	6.5	0.0
Revenue growth	115.3%	-20.5%	-87.4%	46.6%	15.4%	101.9%
Cost of goods sold	6.2	6.9	6.3	15.5	9.8	7.4	4.9	0.0
Gross profit	-1.4	-4.7	-3.6	6.6	5.3	5.7	1.6	0.0
Gross margin	-30.1%	-211.1%	-127.9%	30.0%	35.1%	43.2%	25.0%
Selling, general and administrative	13.2	16.1	20.1	25.3	25.9	22.8	17.1	9.0
Research and development	10.4	11.3	8.0	10.4	18.8	7.5	9.7	4.8
EBITA	-25.1	-32.1	-33.4	-26.9	-37.0	-24.7	-23.2	-12.9
EBITA margin	-526.9%	-1452.0%	-1204.0%	-121.8%	-245.1%	-188.9%	-357.7%
Amortization of intangibles				2.1	2.5		2.1	1.0
EBIT	-25.1	-32.1	-33.4	-29.0	-39.5	-24.7	-25.2	-13.9
EBIT margin	-526.9%	-1452.0%	-1204.0%	-131.3%	-261.6%	-188.9%	-389.3%
Pre-tax income	-26.2	-34.6	-35.8	-27.5	-39.4	-25.9	-24.0	-13.6
Income taxes	0.0	0.0	0.0	0.0	-0.4	-0.3	-4.6	0.0
Tax rate					0.9%	1.3%	19.1%	0.0%
Earnings from continuing ops	-26.2	-34.6	-35.8	-27.5	-39.0	-25.5	-20.8	-13.6
Earnings from discontinued ops	-0.3	-11.2	0.0
Net income	-26.5	-45.8	-49.4	-27.5	-39.0	-25.5	-20.8	-13.6
Net margin	-556.7%	-2074.9%	-1778.8%	-124.4%	-258.6%	-195.4%	-321.5%

Diluted EPS	($0.17)	($0.24)	($0.46)	($0.52)	($1.00)	($0.90)	($1.19)	($1.01)
Shares outstanding (diluted)	149.9	144.2	77.6	53.3	39.1	28.3	17.5	13.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.